Skip to main content
main-content

01.12.2014 | Research Article | Ausgabe 12/2014

Tumor Biology 12/2014

Analysis of circulating microRNA biomarkers for breast cancer detection: a meta-analysis

Zeitschrift:
Tumor Biology > Ausgabe 12/2014
Autoren:
Lihua Liu, Shan Wang, Xiutang Cao, Jianchao Liu
Wichtige Hinweise
L. Liu and S. Wang are the co-first authors.

Abstract

Circulating microRNAs (miRNAs) have been reported to be aberrantly expressed in patients with breast cancer (BC) and thus may serve as potential diagnostic biomarkers. This meta-analysis aimed to assess the potential diagnostic value of using circulating miRNAs for BC. The summary receiver operator characteristic (SROC) curve was used to assess the overall diagnostic performance of circulating miRNA. All analyses were performed using STATA 12.0 software. Thirty-one studies from 16 publications with a total of 1,668 BC patients and 1,111 healthy controls were included in this meta-analysis. Our results showed that the pooled sensitivity (SEN) for miRNAs assays was 0.77 (95 % CI 0.69–0.84), specificity (SPE) was 0.88 (95 % CI 0.79–0.93), positive likelihood ratio (PLR) was 4.2 (95 % CI 3.0–6.0), negative LR (NLR) was 0.29 (95 % CI 0.21–0.40), and diagnostic odds ratio (DOR) was 18 (95 % CI 10–32). The area under the SROC curve (AUC) was 0.89 (95 % CI 0.86–0.91). Subgroup analysis suggested that employing a combination of multiple miRNAs was better than using a single miRNA in SEN (0.88 vs. 0.69), SPE (0.88 vs. 0.89), PLR (6.3 vs. 3.3), NLR (0.14 vs. 0.41), DOR (48 vs. 10), and AUC (0.94 vs. 0.83). In conclusion, our meta-analysis suggested that the expression profiles of circulating miRNAs, especially using a combination of them, have potential to facilitate accurate breast tumor detection. However, there are still challenges that need to be addressed to establish these new biomarkers before they can be applied to routine clinical procedures.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med bestellen und 100 € sparen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 12/2014

Tumor Biology 12/2014 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise